Companion Diagnostic IVD Kit in collaboration with GSK.
Madison, WI USA. (October 3, 2023) Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jemperli (dostarlimab-gxly). The collaboration agreement leverages the companies’ complementary strengths to expand personalized healthcare options to more patients using high quality diagnostic tools and treatments.